Poster Presentation Australian and New Zealand Obesity Society Annual Scientific Conference 2024

Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2 (#241)

Naveed Sattar 1 , Alice YY Cheng 2 , Imane Benabbad 3 , Clare J. Lee 3 , Sophia Kyoungah See 3 , John Leech 3 , Donna Mojdami 3 , Melissa Leung 4
  1. University of Glasgow, Glasgow, UK
  2. University of Toronto, Toronto, ON, Canada
  3. Eli Lilly and Company, Indianapolis, USA
  4. Liverpool hospital, Liverpool BC, NSW, Australia

Aim: In the SURMOUNT-2 (SM-2) trial of adults with overweight/obesity and type 2 diabetes (T2D), tirzepatide (TZP), a once weekly GIP/GLP-1 receptor agonist, significantly reduced body weight (BW) in conjunction with a reduced calorie diet and increased physical activity. This post-hoc analysis assessed the proportion of participants achieving a triple end-point (TEP) composite of BP <130/80 mm Hg, non-HDL <130 mg/dl, and three HbA1c thresholds of <7%, < 6.5% and <5.7% at 72 weeks.

Method: Logistic regression with missing value imputed by mixed model repeated measures, using the efficacy estimand, assessed participants who achieved the TEP goals from SM-2, in the 10mg (N=312) or 15mg (N=311) TZP groups, versus placebo (PBO) (N=315).

Results: Overall baseline mean BW was 100.7 kg, BMI 36.1kg/m2, HbA1c 8.02%, BP 130.5/79.8 mm Hg and non-HDL 132.5 mg/dl. For 15mg TZP, 33.8%, 32.8%, and 25.9% of participants achieved the TEP composite versus 7.5%, 3.9%, and 0.7% for PBO (HbA1c <7%, <6.5% & <5.7% respectively) at 72 weeks. Findings for the TZP 10mg group were similar to those observed in the 15mg group.

Conclusion: In this post-hoc analysis in people with T2D and overweight/obesity, higher proportion of participants receiving TZP achieved the TEP composite, compared to PBO. This suggests that TZP can help people with obesity and T2D achieve multiple clinical goals, in addition to meaningful weight loss, important for improving cardiometabolic health.